drugset / Trial / NCT05751850
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.
Timeline
- Start
- 2023-06-13
- Primary completion
- 2024-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcium folinate | Unknown | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Subject | HR070803 | Unknown | — | — |
| Comparator | Nab-paclitaxel | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |
Indications
No indication recorded.